A Phase 2 interventional study of TAK-079 and TAK-079 Placebo in Myasthenia Gravis, sponsored by Takeda. Completed at 50 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-02.
Sponsored by Takeda · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 144 studies in Myasthenia Gravis with a site in United States — 53 open to participants now, 73 under way, 25 of them phase 3. Myasthenia Gravis · United States.
Among the 144 studies in Myasthenia Gravis with a site in United States, this one is the 65th largest by enrollment of the 108 interventional ones that give a count, is one of 4 that started in 2020, is one of 26 in phase 2, and was the 51st registered.
331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.
Browse Myasthenia Gravis studies →53 of the 144 studies in Myasthenia Gravis with a site in United States are open now. Recruiting first, the newest first:
TG Therapeutics, Inc. · Sites in United States
Ages 18+
UCB Biopharma SRL · Sites in United States, China, France and 4 more countries
Ages 18+
George Washington University · Sites in United States
Ages 18+
Amgen · Sites in United States, Argentina, Brazil and 5 more countries
Ages 2–17
argenx · Sites in United States, Belgium, Greece and 4 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
144 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 38 · Phase 3 51 · Phase 4 3
First in 1995; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 44 across 218 interventional studies indexed under Myasthenia Gravis.
Median enrollment 56 across the 108 interventional studies, 226 across the 36 observational. Of the 64 that completed or were terminated, 41 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
96 of 144 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Takeda has 1 study filed under Myasthenia Gravis — fewer than ten, so there is no comparison to draw.
18 of the studies in Myasthenia Gravis with a site in United States that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06607627Phase 3Alexion Pharmaceuticals, Inc.PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis | 2026-12-15 |
| NCT06799247Phase 3Cartesian TherapeuticsInvestigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis | 2026-12-30 |
| NCT04833894Phase 3argenxEvaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis | 2027-03 |
| NCT06456580Phase 3Vor BiopharmaA Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | 2027-03 |
| NCT06517758Phase 3Novartis PharmaceuticalsA Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. | 2027-04-30 |
Add all 18 to your calendar (.ics) → With an account.
Among the 144 studies in Myasthenia Gravis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Myasthenia gravis is an autoimmune condition that causes muscle weakness. Autoimmune means the body makes antibodies that attack its own cells and tissues. These types of antibodies are also known as autoantibodies. People with generalized myasthenia gravis have a weakness in many muscles.
TAK-079 is a medicine to help people with generalized myasthenia gravis.
The main aim of this study is to check if people with generalized myasthenia gravis have side effects from 2 doses of TAK-079. Other aims are to learn if TAK-079 improves their clinical condition and lowers their autoantibody levels.
At the first visit, the study doctor will check if each person can take part. For those who can take part, participants will continue with their standard medicines for this condition during the study. Each participant will have a check-up by the study doctor.
Then, the participants will have 1 of 3 treatments:
Participants will not know which treatment they received, nor will their study doctors. This is to help make sure the results are more reliable.
For each treatment, participants will receive injections just under the skin, once a week for 8 weeks. The study doctors will check for side effects from the study treatments. The study doctors can stop or delay the injections in each participant if needed.
Then, the study doctors will continue to check for side effects for up to 24 weeks after treatment. They will also check the clinical condition of the participants, including their autoantibody levels.
Myasthenia gravis (MG) is an autoimmune disorder in which autoantibodies, such as those targeting the nicotinic acetylcholine receptor (AChR) or muscle specific kinase (MuSK), interfere with neuromuscular transmission, resulting in fatigue and weakness.
The drug being tested in this study is called TAK-079. TAK-079 is being tested to treat people who have generalized myasthenia gravis.
Main Inclusion Criteria:
Main Exclusion Criteria:
(COPD) or asthma with a pre-bronchodilatory (FEV1) \<50% of predicted normal.
Note: FEV1 testing is required for participants suspected of having COPD or asthma.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAK-079 placebo-matching injection, subcutaneously (SC), once weekly in combination with standard background therapy for 8 weeks.
Drug: TAK-079 Placebo
TAK-079 300 mg injection, SC, once weekly in combination with standard background therapy for 8 weeks.
Drug: TAK-079
TAK-079 600 mg injection, SC, once weekly in combination with standard background therapy for 8 weeks.
Drug: TAK-079
TAK-079 subcutaneous injection
Also known as: Mezagitamab
TAK-079 placebo-matching subcutaneous injection
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Grade 3 or Higher TEAEs, and Adverse Event (AE) Leading to TAK-079 Discontinuation
AE is defined as any untoward medical occurrence in clinical investigation participant administered drug; it does not necessarily have to have causal relationship with this treatment. TEAE is defined as AE with onset that occurs after receiving study drug. SAE is an adverse event resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Severity of TEAEs was graded using National cancer institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 definitions of Grade 1 through Grade 5 wherein Grade 1=mild symptoms, Grade 2=moderate symptoms, Grade 3=Severe or medically significant but not immediately life-threatening, Grade 4=life-threatening consequences and Grade 5=death related to AEs. Percentages are rounded off to whole number at single decimal.
Time frame: From signing the informed consent form up to end of long-term follow-up (up to Week 32)
Change From Baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale Score
Participant-reported scale to assess MG symptoms to evaluate capacity to perform activities of daily living. Each question is graded on a 4-point scale from 0=normal to 3=severe with a total score of 0 to 24; the higher score indicates greater functional impairment and disability. Negative change indicates improvement. Mixed-effects model for repeated measures (MMRM) was used for the analysis.
Time frame: Baseline up to Week 32
Change From Baseline in Quantitative Myasthenia Gravis (QMG) Scale Score
Physician-reported scale to assess MG disease severity by quantifying several body functions by physical exam. Each question is graded on a 4-point scale from 0=normal to 3=severe with a total score of 0 to 39; the higher score indicates greater disease burden. Negative change indicates improvement. MMRM was used for the analysis.
Time frame: Baseline up to Week 32
Change From Baseline in Myasthenia Gravis Composite (MGC) Scale Score
An assessment scale of MG disease activity based on a combination of participant- and physician-reported items. Items are scored based on 4 potential levels of impact: normal, mild, moderate, or severe with a total score of 0 to 50; the higher score indicates worse MG disease activity. Negative change indicates improvement. MMRM was used for the analysis.
Time frame: Baseline up to Week 32
Change From Baseline in Revised 15-item Myasthenia Gravis Quality of Life Scale (MG-QoL15r) Scale Score
A participant-reported score that assesses the participant's perception of impairment and disability and the degree to which the participant tolerates disease manifestations. Each question is graded on a 3-point scale from 0=normal to 2=severe with a total score of 0 to 30; the higher score indicates worse MG disease activity. Negative change indicates improvement. MMRM was used for the analysis.
Time frame: Baseline up to Week 32
Change From Baseline in Anti-acetylcholine Receptor (AChR) Antibody Levels
Clinical laboratory evaluations of anti-AChR antibodies were tested to monitor disease activity. MMRM was used for the analysis.
Time frame: Baseline up to Week 32
Change From Baseline in Anti- Muscle-specific Tyrosine Kinase (MuSK) Titer Levels
Clinical laboratory evaluations of anti-MuSK antibodies were tested to monitor disease activity. Data is reported for participants who were positive for anti-MuSK antibodies at baseline.
Time frame: Baseline up to Week 32
Percentage of Participants With 2-point Reduction in MG-ADL Total Score
The percentage of responders with at least a 2-point reduction in MG-ADL total score from baseline is reported. MG-ADL is a participant-reported scale to assess MG symptoms to evaluate capacity to perform activities of daily living. Each question is graded on a 4-point scale from 0=normal to 3=severe with a total score of 0 to 24; the higher score indicates greater functional impairment and disability. Percentages are rounded off to whole number at the nearest decimal.
Time frame: At Weeks 4, 6, 8, 10, 12, 14, 16, 20, 24, 28 and 32
Percentage of Participants With 3-point Reduction in QMG Total Score
The percentage of responders with at least a 3-point reduction in QMG total score from baseline is reported. QMG is a physician-reported scale to assess MG disease severity by quantifying several body functions by physical exam. Each question is graded on a 4-point scale from 0=normal to 3=severe with a total score of 0 to 39; the higher score indicates greater disease burden. Percentages are rounded off to whole number at the nearest decimal.
Time frame: At Weeks 4, 6, 8, 10, 12, 14, 16, 20, 24, 28 and 32
Percentage of Participants With 3-point Reduction in MGC Total Score
The percentage of responders with at least a 3-point reduction in MGC total score from baseline is reported. MGC is an assessment scale of MG disease activity based on a combination of participant- and physician-reported items. Items are scored based on 4 potential levels of impact: normal, mild, moderate, or severe with a total score of 0 to 50; the higher score indicates worse MG disease activity. Percentages are rounded off to whole number at the nearest decimal.
Time frame: At Weeks 4, 6, 8, 10, 12, 14, 16, 20, 24, 28 and 32
Participants took part in the study at 15 investigative sites in the United States, Spain, Poland, Serbia, and Canada from 14 January 2020 to 12 July 2022.
| Milestone | TAK-079 Placebo-matching | TAK-079 300 mg | TAK-079 600 mg |
|---|---|---|---|
| Started | 12 | 12 | 12 |
| Completed | 12 | 10 | 10 |
| Not completed | 0 | 2 | 2 |
| Withdrew: Withdrawal by subject | 0 | 2 | 2 |
AE is defined as any untoward medical occurrence in clinical investigation participant administered drug; it does not necessarily have to have causal relationship with this treatment. TEAE is defined as AE with onset that occurs after receiving study drug. SAE is an adverse event resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Severity of TEAEs was graded using National cancer institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 definitions of Grade 1 through Grade 5 wherein Grade 1=mild symptoms, Grade 2=moderate symptoms, Grade 3=Severe or medically significant but not immediately life-threatening, Grade 4=life-threatening consequences and Grade 5=death related to AEs. Percentages are rounded off to whole number at single decimal.
| percentage of participants | TAK-079 Placebo-matching | TAK-079 300 mg | TAK-079 600 mg |
|---|---|---|---|
| TEAE | 66.7 | 75.0 | 91.7 |
| SAE | 8.3 | 8.3 | 8.3 |
| Grade 3 or Higher TEAEs | 16.7 | 8.3 | 8.3 |
| AE Leading to TAK-079 Discontinuation | 0.0 | 0.0 | 0.0 |
Participant-reported scale to assess MG symptoms to evaluate capacity to perform activities of daily living. Each question is graded on a 4-point scale from 0=normal to 3=severe with a total score of 0 to 24; the higher score indicates greater functional impairment and disability. Negative change indicates improvement. Mixed-effects model for repeated measures (MMRM) was used for the analysis.
| score on a scale | TAK-079 Placebo-matching | TAK-079 300 mg | TAK-079 600 mg |
|---|---|---|---|
| Change From Baseline at Week 4 | -2.8 ± 2.67 | -2.5 ± 2.47 | -1.8 ± 1.66 |
| Change From Baseline at Week 6 | -4.0 ± 2.73 | -4.2 ± 2.64 | -2.3 ± 2.15 |
| Change From Baseline at Week 8 | -3.8 ± 2.80 | -4.3 ± 3.10 | -2.0 ± 3.16 |
| Change From Baseline at Week 10 | -4.0 ± 3.52 | -5.0 ± 2.41 | -2.0 ± 2.79 |
| Change From Baseline at Week 12 | -4.2 ± 3.19 | -4.2 ± 2.56 | -2.5 ± 2.68 |
| Change From Baseline at Week 14 | -4.0 ± 4.38 | -4.8 ± 2.20 | -2.0 ± 3.30 |
| Change From Baseline at Week 16 | -4.1 ± 3.21 | -4.3 ± 2.79 | -3.1 ± 3.48 |
| Change From Baseline at Week 20 | — | -3.9 ± 3.60 | -2.9 ± 3.11 |
| Change From Baseline at Week 24 | — | -4.1 ± 3.62 | -3.0 ± 3.57 |
| Change From Baseline at Week 28 | — | -3.9 ± 3.96 | -3.1 ± 3.37 |
| Change From Baseline at Week 32 | — | -2.3 ± 4.61 | -2.8 ± 3.99 |
Physician-reported scale to assess MG disease severity by quantifying several body functions by physical exam. Each question is graded on a 4-point scale from 0=normal to 3=severe with a total score of 0 to 39; the higher score indicates greater disease burden. Negative change indicates improvement. MMRM was used for the analysis.
| score on a scale | TAK-079 Placebo-matching | TAK-079 300 mg | TAK-079 600 mg |
|---|---|---|---|
| Change From Baseline at Week 4 | -1.0 ± 2.34 | -2.0 ± 2.70 | -0.2 ± 2.89 |
| Change From Baseline at Week 6 | -0.9 ± 1.76 | -2.5 ± 3.24 | -1.3 ± 3.10 |
| Change From Baseline at Week 8 | -1.0 ± 2.30 | -3.4 ± 3.35 | -0.9 ± 3.27 |
| Change From Baseline at Week 10 | -1.4 ± 2.87 | -3.2 ± 3.09 | -0.7 ± 4.03 |
| Change From Baseline at Week 12 | -2.8 ± 2.68 | -3.9 ± 2.55 | -0.8 ± 3.51 |
| Change From Baseline at Week 14 | -1.9 ± 3.11 | -3.5 ± 2.51 | 0.6 ± 4.65 |
| Change From Baseline at Week 16 | -1.2 ± 3.22 | -3.3 ± 3.43 | -0.3 ± 4.81 |
| Change From Baseline at Week 20 | — | -1.9 ± 3.56 | -0.5 ± 4.27 |
| Change From Baseline at Week 24 | — | -2.2 ± 4.47 | -0.6 ± 3.78 |
| Change From Baseline at Week 28 | — | -1.7 ± 3.80 | -0.8 ± 4.52 |
| Change From Baseline at Week 32 | — | -0.7 ± 4.27 | -0.1 ± 4.79 |
An assessment scale of MG disease activity based on a combination of participant- and physician-reported items. Items are scored based on 4 potential levels of impact: normal, mild, moderate, or severe with a total score of 0 to 50; the higher score indicates worse MG disease activity. Negative change indicates improvement. MMRM was used for the analysis.
| score on a scale | TAK-079 Placebo-matching | TAK-079 300 mg | TAK-079 600 mg |
|---|---|---|---|
| Change From Baseline at Week 4 | -4.2 ± 3.69 | -4.9 ± 3.82 | -1.1 ± 5.92 |
| Change From Baseline at Week 6 | -7.3 ± 4.29 | -6.1 ± 5.24 | -4.9 ± 4.74 |
| Change From Baseline at Week 8 | -5.5 ± 4.03 | -7.4 ± 4.63 | -2.4 ± 6.10 |
| Change From Baseline at Week 10 | -7.8 ± 5.86 | -7.6 ± 5.07 | -2.6 ± 6.55 |
| Change From Baseline at Week 12 | -7.3 ± 5.00 | -8.5 ± 3.11 | -5.1 ± 5.11 |
| Change From Baseline at Week 14 | -6.1 ± 6.52 | -9.7 ± 3.83 | -0.9 ± 8.25 |
| Change From Baseline at Week 16 | -6.6 ± 4.95 | -9.2 ± 5.18 | -2.9 ± 6.45 |
| Change From Baseline at Week 20 | — | -7.3 ± 5.20 | -2.6 ± 7.21 |
| Change From Baseline at Week 24 | — | -7.1 ± 5.78 | -3.3 ± 7.30 |
| Change From Baseline at Week 28 | — | -5.6 ± 6.40 | -4.1 ± 7.59 |
| Change From Baseline at Week 32 | — | -3.4 ± 8.13 | -2.5 ± 8.07 |
A participant-reported score that assesses the participant's perception of impairment and disability and the degree to which the participant tolerates disease manifestations. Each question is graded on a 3-point scale from 0=normal to 2=severe with a total score of 0 to 30; the higher score indicates worse MG disease activity. Negative change indicates improvement. MMRM was used for the analysis.
| score on a scale | TAK-079 Placebo-matching | TAK-079 300 mg | TAK-079 600 mg |
|---|---|---|---|
| Change From Baseline at Week 4 | -3.1 ± 3.85 | -3.9 ± 4.46 | -3.2 ± 4.43 |
| Change From Baseline at Week 6 | -4.3 ± 4.11 | -5.8 ± 6.00 | -3.4 ± 3.53 |
| Change From Baseline at Week 8 | -3.2 ± 4.00 | -5.6 ± 6.53 | -3.3 ± 3.74 |
| Change From Baseline at Week 10 | -2.5 ± 6.12 | -6.3 ± 6.07 | -3.9 ± 3.70 |
| Change From Baseline at Week 12 | -2.5 ± 5.32 | -6.1 ± 7.25 | -4.1 ± 4.40 |
| Change From Baseline at Week 14 | -2.0 ± 7.06 | -6.4 ± 6.98 | -0.9 ± 5.49 |
| Change From Baseline at Week 16 | -3.8 ± 4.44 | -5.8 ± 6.83 | -2.3 ± 6.43 |
| Change From Baseline at Week 20 | — | -3.3 ± 7.01 | -4.7 ± 5.48 |
| Change From Baseline at Week 24 | — | -7.1 ± 7.95 | -3.8 ± 5.31 |
| Change From Baseline at Week 28 | — | -4.8 ± 10.36 | -4.0 ± 6.16 |
| Change From Baseline at Week 32 | — | -6.2 ± 7.31 | -2.4 ± 4.78 |
Clinical laboratory evaluations of anti-AChR antibodies were tested to monitor disease activity. MMRM was used for the analysis.
| nmol/L | TAK-079 Placebo-matching | TAK-079 300 mg | TAK-079 600 mg |
|---|---|---|---|
| Change From Baseline at Week 2 | 6.300 ± 25.3514 | -19.452 ± 50.5551 | -3.450 ± 5.7767 |
| Change From Baseline at Week 3 | -3.989 ± 22.9732 | -14.821 ± 44.4776 | 2.509 ± 17.5221 |
| Change From Baseline at Week 4 | 0.976 ± 11.7759 | -24.253 ± 51.2627 | 13.680 ± 87.1669 |
| Change From Baseline at Week 5 | -8.199 ± 13.9571 | -32.251 ± 58.3701 | -9.831 ± 26.2188 |
| Change From Baseline at Week 6 | -19.152 ± 49.2221 | -27.518 ± 52.6672 | -2.148 ± 23.2543 |
| Change From Baseline at Week 7 | -11.235 ± 26.2159 | -33.261 ± 56.3495 | -9.882 ± 16.2972 |
| Change From Baseline at Week 8 | 7.731 ± 27.8994 | -39.386 ± 72.3110 | -5.668 ± 10.4493 |
| Change From Baseline at Week 10 | -37.473 ± 120.9186 | -37.083 ± 60.8092 | -6.654 ± 7.8236 |
| Change From Baseline at Week 12 | -0.832 ± 31.0318 | -38.430 ± 64.4594 | -7.827 ± 11.2120 |
| Change From Baseline at Week 14 | 12.729 ± 49.8823 | -40.771 ± 74.3624 | -8.058 ± 15.8407 |
| Change From Baseline at Week 16 | 3.501 ± 9.8729 | -49.843 ± 77.6316 | -4.909 ± 8.8478 |
| Change From Baseline at Week 20 | — | -52.217 ± 83.1537 | -4.378 ± 7.7297 |
| Change From Baseline at Week 24 | — | -43.079 ± 77.4438 | -4.802 ± 10.5639 |
| Change From Baseline at Week 28 | — | -73.786 ± 111.0044 | -6.044 ± 11.3755 |
| Change From Baseline at Week 32 | — | -51.296 ± 67.3437 | -5.485 ± 11.8380 |
Clinical laboratory evaluations of anti-MuSK antibodies were tested to monitor disease activity. Data is reported for participants who were positive for anti-MuSK antibodies at baseline.
| titer | TAK-079 Placebo-matching | TAK-079 300 mg | TAK-079 600 mg |
|---|---|---|---|
| Change From Baseline at Week 2 | 0.0 ± NA | -160.0 ± 226.27 | — |
| Change From Baseline at Week 3 | 0.0 ± NA | -200.0 ± 169.71 | — |
| Change From Baseline at Week 4 | 0.0 ± NA | -240.0 ± 339.41 | — |
| Change From Baseline at Week 5 | 0.0 ± NA | -240.0 ± 339.41 | — |
| Change From Baseline at Week 6 | 0.0 ± NA | -240.0 ± 339.41 | — |
| Change From Baseline at Week 7 | 0.0 ± NA | -240.0 ± 339.41 | — |
| Change From Baseline at Week 8 | 0.0 ± NA | -280.0 ± 395.98 | — |
| Change From Baseline at Week 10 | 0.0 ± NA | -280.0 ± 395.98 | — |
| Change From Baseline at Week 12 | 0.0 ± NA | -300.0 ± 424.26 | — |
| Change From Baseline at Week 14 | 0.0 ± NA | -300.0 ± 424.26 | — |
| Change From Baseline at Week 16 | 0.0 ± NA | -300.0 ± 424.26 | — |
| Change From Baseline at Week 20 | — | 0.0 ± NA | — |
| Change From Baseline at Week 24 | — | -310.0 ± 438.41 | — |
| Change From Baseline at Week 28 | — | -310.0 ± 438.41 | — |
| Change From Baseline at Week 32 | — | -310.0 ± 438.41 | — |
The percentage of responders with at least a 2-point reduction in MG-ADL total score from baseline is reported. MG-ADL is a participant-reported scale to assess MG symptoms to evaluate capacity to perform activities of daily living. Each question is graded on a 4-point scale from 0=normal to 3=severe with a total score of 0 to 24; the higher score indicates greater functional impairment and disability. Percentages are rounded off to whole number at the nearest decimal.
| percentage of participants | TAK-079 Placebo-matching | TAK-079 300 mg | TAK-079 600 mg |
|---|---|---|---|
| Week 4 | 50.00 | 75.00 | 58.33 |
| Week 6 | 91.67 | 75.00 | 58.33 |
| Week 8 | 83.33 | 66.67 | 66.67 |
| Week 10 | 83.33 | 83.33 | 50.00 |
| Week 12 | 75.00 | 75.00 | 50.00 |
| Week 14 | 66.67 | 75.00 | 50.00 |
| Week 16 | 66.67 | 66.67 | 33.33 |
| Week 20 | 0.0 | 66.67 | 58.33 |
| Week 24 | 0.0 | 58.33 | 58.33 |
| Week 28 | 0.0 | 58.33 | 58.33 |
| Week 32 | 0.0 | 41.67 | 41.67 |
The percentage of responders with at least a 3-point reduction in QMG total score from baseline is reported. QMG is a physician-reported scale to assess MG disease severity by quantifying several body functions by physical exam. Each question is graded on a 4-point scale from 0=normal to 3=severe with a total score of 0 to 39; the higher score indicates greater disease burden. Percentages are rounded off to whole number at the nearest decimal.
| percentage of participants | TAK-079 Placebo-matching | TAK-079 300 mg | TAK-079 600 mg |
|---|---|---|---|
| Week 4 | 25.00 | 50.00 | 16.67 |
| Week 6 | 16.67 | 41.67 | 33.33 |
| Week 8 | 33.33 | 66.67 | 33.33 |
| Week 10 | 33.33 | 66.67 | 33.33 |
| Week 12 | 41.67 | 75.00 | 25.00 |
| Week 14 | 33.33 | 66.67 | 25.00 |
| Week 16 | 33.33 | 58.33 | 33.33 |
| Week 20 | 0.0 | 41.67 | 33.33 |
| Week 24 | 0.0 | 41.67 | 33.33 |
| Week 28 | 0.0 | 41.67 | 25.00 |
| Week 32 | 0.0 | 16.67 | 16.67 |
The percentage of responders with at least a 3-point reduction in MGC total score from baseline is reported. MGC is an assessment scale of MG disease activity based on a combination of participant- and physician-reported items. Items are scored based on 4 potential levels of impact: normal, mild, moderate, or severe with a total score of 0 to 50; the higher score indicates worse MG disease activity. Percentages are rounded off to whole number at the nearest decimal.
| percentage of participants | TAK-079 Placebo-matching | TAK-079 300 mg | TAK-079 600 mg |
|---|---|---|---|
| Week 4 | 66.67 | 75.00 | 41.67 |
| Week 6 | 83.33 | 66.67 | 58.33 |
| Week 8 | 83.33 | 83.33 | 58.33 |
| Week 10 | 83.33 | 75.00 | 50.00 |
| Week 12 | 75.00 | 91.67 | 58.33 |
| Week 14 | 66.67 | 83.33 | 50.00 |
| Week 16 | 66.67 | 75.00 | 41.67 |
| Week 20 | 0.0 | 75.00 | 58.33 |
| Week 24 | 0.0 | 66.67 | 50.00 |
| Week 28 | 0.0 | 58.33 | 50.00 |
| Week 32 | 0.0 | 41.67 | 25.00 |
Collected over From signing the informed consent form up to end of long-term follow-up (up to Week 32). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TAK-079 Placebo-matching | 0/12 (0%) | 1/12 (8.3%) | 8/12 (66.7%) |
| TAK-079 300 mg | 0/12 (0%) | 1/12 (8.3%) | 9/12 (75%) |
| TAK-079 600 mg | 0/12 (0%) | 1/12 (8.3%) | 11/12 (91.7%) |
| Event | TAK-079 Placebo-matching | TAK-079 300 mg | TAK-079 600 mg |
|---|---|---|---|
| EnteritisGastrointestinal disorders | 1/12 | 0/12 | 0/12 |
| GastroenteritisInfections and infestations | 1/12 | 0/12 | 0/12 |
| Myasthenia gravisNervous system disorders | 0/12 | 0/12 | 1/12 |
| Suicidal ideationPsychiatric disorders | 0/12 | 1/12 | 0/12 |
| Event | TAK-079 Placebo-matching | TAK-079 300 mg | TAK-079 600 mg |
|---|---|---|---|
| ChillsGeneral disorders | 0/12 | 0/12 | 3/12 |
| PyrexiaGeneral disorders | 1/12 | 2/12 | 3/12 |
| FatigueGeneral disorders | 0/12 | 1/12 | 2/12 |
| NasopharyngitisInfections and infestations | 1/12 | 0/12 | 2/12 |
| Abdominal wall abscessInfections and infestations | 1/12 | 0/12 | 0/12 |
| Abscess limbInfections and infestations | 0/12 | 0/12 | 1/12 |
| Alanine aminotransferase increasedInvestigations | 0/12 | 0/12 | 1/12 |
| AnaemiaBlood and lymphatic system disorders | 0/12 | 0/12 | 1/12 |
| Angle closure glaucomaEye disorders | 0/12 | 0/12 | 1/12 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/12 | 0/12 | 1/12 |
Safety Analysis Set included participants who received at least 1 dose of study drug.
| Age, Continuous(years) | TAK-079 Placebo-matching | TAK-079 300 mg | TAK-079 600 mg | Total |
|---|---|---|---|---|
| Mean | 46.5 ± 18.03 | 45.3 ± 12.47 | 56.3 ± 14.42 | 49.4 ± 15.54 |
| Sex: Female, Male(Participants) | TAK-079 Placebo-matching | TAK-079 300 mg | TAK-079 600 mg | Total |
|---|---|---|---|---|
| Female | 9 | 6 | 7 | 22 |
| Male | 3 | 6 | 5 | 14 |
| Ethnicity (NIH/OMB)(Participants) | TAK-079 Placebo-matching | TAK-079 300 mg | TAK-079 600 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 1 | 3 |
| Not Hispanic or Latino | 9 | 12 | 11 | 32 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | TAK-079 Placebo-matching | TAK-079 300 mg | TAK-079 600 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 1 |
| White | 10 | 12 | 11 | 33 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Region of Enrollment(Participants) | TAK-079 Placebo-matching | TAK-079 300 mg | TAK-079 600 mg | Total |
|---|---|---|---|---|
| Canada | 0 | 1 | 1 | 2 |
| Poland | 1 | 2 | 2 | 5 |
| Serbia | 5 | 7 | 5 | 17 |
| Spain | 3 | 0 | 1 | 4 |
| United States | 3 | 2 | 3 | 8 |
| Height(cm) | TAK-079 Placebo-matching | TAK-079 300 mg | TAK-079 600 mg | Total |
|---|---|---|---|---|
| Mean | 164.67 ± 9.435 | 175.39 ± 8.911 | 171.38 ± 10.910 | 170.48 ± 10.511 |
| Weight(kg) | TAK-079 Placebo-matching | TAK-079 300 mg | TAK-079 600 mg | Total |
|---|---|---|---|---|
| Mean | 85.11 ± 25.607 | 86.28 ± 21.132 | 88.38 ± 25.672 | 86.59 ± 23.568 |
| Body Mass Index (BMI)(kg/m^2) | TAK-079 Placebo-matching | TAK-079 300 mg | TAK-079 600 mg | Total |
|---|---|---|---|---|
| Mean | 31.33 ± 8.867 | 27.74 ± 4.852 | 30.22 ± 9.315 | 29.76 ± 7.855 |
4 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jan 2020 to primary completion in Jul 2022, 29 months.
Results were first posted in Jun 2023, 10 months after primary completion.
Of 22 phase 2 interventional studies under Myasthenia Gravis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 30. This study's 29 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mezagitamab